Home/Filings/4/0001694665-23-000041
4//SEC Filing

McHale Duncan 4

Accession 0001694665-23-000041

CIK 0001694665other

Filed

May 8, 8:00 PM ET

Accepted

May 9, 4:08 PM ET

Size

7.1 KB

Accession

0001694665-23-000041

Insider Transaction Report

Form 4
Period: 2023-05-07
McHale Duncan
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-05-07+130,000164,246 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-05-07130,000390,000 total
    Common Stock (130,000 underlying)
Footnotes (2)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
  • [F2]The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date.

Issuer

Evelo Biosciences, Inc.

CIK 0001694665

Entity typeother

Related Parties

1
  • filerCIK 0001738896

Filing Metadata

Form type
4
Filed
May 8, 8:00 PM ET
Accepted
May 9, 4:08 PM ET
Size
7.1 KB